The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter random assignment phase II study of irinotecan and flavopiridol versus irinotecan alone for patients with p53 wild-type gastric adenocarcinoma (NCI 8060).
Yelena Yuriy Janjigian
No relevant relationships to disclose
Laura H. Tang
No relevant relationships to disclose
Stephen Shibata
No relevant relationships to disclose
David Paul Kelsen
No relevant relationships to disclose
Michal Segal
No relevant relationships to disclose
Catherine Cheng
No relevant relationships to disclose
Gary K. Schwartz
No relevant relationships to disclose
L. Austin Doyle
No relevant relationships to disclose
Manish A. Shah
No relevant relationships to disclose